StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for MTNB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.56 | $0.54 | -3.57% | 0.0M |
| 05-19 | $0.55 | $0.56 | +1.13% | 6.3M |
| 05-20 | $0.48 | $0.64 | +31.85% | 0.3M |
| 05-21 | $0.59 | $0.67 | +13.64% | 0.1M |
| 05-22 | $0.65 | $0.70 | +8.36% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $1.10M | $1.10M | $1.10M | $1.10M |
Operating Income | $-23.77M | $-17.88M | $-11.74M | $-5.59M |
Net Income | $-22.94M | $-17.63M | $-11.57M | $-5.51M |
EPS (Diluted) | $-5.28 | $-4.06 | $-0.05 | $-0.03 |
Total Assets | $25.10M | $29.79M | $34.02M | $38.26M |
Total Liabilities | $5.86M | $6.64M | $6.17M | $5.64M |
Cash & Equivalents | $4.79M | $6.41M | $9.74M | $5.74M |
Free Cash Flow OCF − CapEx | $-15.50M | $-10.92M | $-6.48M | Not available |
Shares Outstanding | 4.35M | 217.26M | 217.26M | 217.26M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.